BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karabicici M, Azbazdar Y, Ozhan G, Senturk S, Firtina Karagonlar Z, Erdal E. Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7. Front Cell Dev Biol 2021;9:639779. [PMID: 34458250 DOI: 10.3389/fcell.2021.639779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Han H, Wang L, Wang W, Yang M, Qin Y. Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.988956] [Reference Citation Analysis]
2 Yu ZL, Liu J, Ning ZK, Tian HK, Wu X, Huang YF, Wu ZC, Zong Z, Zhou TC. The TGF‐β/Smad 2/3 signaling pathway is involved in Musashi2‐induced invasion and metastasis of colorectal cancer. Molecular Carcinogenesis 2022. [DOI: 10.1002/mc.23484] [Reference Citation Analysis]
3 Leung RWH, Lee TKW. Wnt/β-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers 2022;14:5468. [DOI: 10.3390/cancers14215468] [Reference Citation Analysis]
4 Azbazdar Y, Demirci Y, Heger G, Karabicici M, Ozhan G. Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/β-catenin signaling and tumor growth.. [DOI: 10.1101/2022.08.28.505578] [Reference Citation Analysis]
5 Man KF, Ma S. Mechanisms of resistance to tyrosine kinase inhibitors in liver cancer stem cells and potential therapeutic approaches. Essays Biochem 2022:EBC20220001. [PMID: 35818992 DOI: 10.1042/EBC20220001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Xing Y, Qin F, Zhai Y, Yang J, Yan Y, Li D, Zhang H, Hu R, Xu X, Cao X, Huang G, Liu X, Korivi M. Association of Clinical Features of Colorectal Cancer with Circulating Tumor Cells and Systemic Inflammatory Markers. Disease Markers 2022;2022:1-8. [DOI: 10.1155/2022/5105599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang P, Qin C, Liu N, Zhou X, Chu X, Lv F, Gu Y, Yin L, Liu J, Zhou J, Huo M. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. β-Catenin signaling in hepatocellular carcinoma. J Clin Invest 2022;132:e154515. [PMID: 35166233 DOI: 10.1172/JCI154515] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
9 Karabicici M, Azbazdar Y, Iscan E, Ozhan G. Misregulation of Wnt Signaling Pathways at the Plasma Membrane in Brain and Metabolic Diseases. Membranes (Basel) 2021;11:844. [PMID: 34832073 DOI: 10.3390/membranes11110844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]